Shots:

• Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML  
• The companies will utilize ASCO’s CancerLinQ Discovery database of de-identified cancer patient records to improve understanding of responses in patients- AML treatment patterns- disease progression and opportunities for improved QoL
• The CancerLinQ is a platform designed to monitor- coordinate and improve cancer outcomes with collection- aggregation- curation and analysis of data. Concerto HealthAI and CancerLinQ exclusive collaborated to advance critical research and improve outcomes in multiple cancers

Ref: Astellas | Image: Astellas